9 assets in Pancreatic Endocrine Carcinoma

Therapeutic assets addressing Pancreatic Endocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Pancreatic Endocrine Carcinoma	ECOG-ACRIN Cancer Research Group	P2	B (60)
Capecitabine Pancreatic Endocrine Carcinoma	Alliance for Clinical Trials in Oncology	P2	B (57)
Oxodotreotide Pancreatic Endocrine Carcinoma	Alliance for Clinical Trials in Oncology	P2	B (57)
Cis-Diamminedichloroplatinum Ii Pancreatic Endocrine Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
esk981 Pancreatic Endocrine Carcinoma	University of Michigan Rogel Cancer Center	P2	CCC (53)
Etoposide Pancreatic Endocrine Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Ipilimumab Pancreatic Endocrine Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Pancreatic Endocrine Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tarlatamab Pancreatic Endocrine Carcinoma	Inkeun Park	P2	CCC (53)